Canaccord Genuity Group restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR - Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $14.00 target price on the stock.
Several other equities research analysts also recently issued reports on VYGR. Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a research report on Wednesday, October 16th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday. Wedbush dropped their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, August 7th. Leerink Partners began coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 price target for the company. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Sunday. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Voyager Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $17.00.
Read Our Latest Research Report on VYGR
Voyager Therapeutics Trading Down 7.0 %
Shares of NASDAQ VYGR traded down $0.47 during mid-day trading on Thursday, hitting $6.22. The company had a trading volume of 708,684 shares, compared to its average volume of 642,515. The company has a market capitalization of $339.20 million, a PE ratio of 8.76 and a beta of 0.89. The firm has a 50-day simple moving average of $6.63 and a two-hundred day simple moving average of $7.52. Voyager Therapeutics has a one year low of $5.71 and a one year high of $11.72.
Insiders Place Their Bets
In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company's stock, valued at $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.53% of the company's stock.
Institutional Investors Weigh In On Voyager Therapeutics
Large investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its stake in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock worth $37,000 after acquiring an additional 1,300 shares in the last quarter. Plato Investment Management Ltd bought a new position in Voyager Therapeutics during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. boosted its stake in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after acquiring an additional 4,098 shares in the last quarter. Intech Investment Management LLC bought a new position in Voyager Therapeutics during the third quarter worth $74,000. Finally, SG Americas Securities LLC bought a new position in Voyager Therapeutics during the second quarter worth $85,000. Institutional investors and hedge funds own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Featured Articles
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
